174 related articles for article (PubMed ID: 9934941)
1. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
Potenza MN; Holmes JP; Kanes SJ; McDougle CJ
J Clin Psychopharmacol; 1999 Feb; 19(1):37-44. PubMed ID: 9934941
[TBL] [Abstract][Full Text] [Related]
2. Open-label study of olanzapine in children with pervasive developmental disorder.
Kemner C; Willemsen-Swinkels SH; de Jonge M; Tuynman-Qua H; van Engeland H
J Clin Psychopharmacol; 2002 Oct; 22(5):455-60. PubMed ID: 12352267
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
Malone RP; Cater J; Sheikh RM; Choudhury MS; Delaney MA
J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):887-94. PubMed ID: 11501687
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
Hollander E; Wasserman S; Swanson EN; Chaplin W; Schapiro ML; Zagursky K; Novotny S
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):541-8. PubMed ID: 17069543
[TBL] [Abstract][Full Text] [Related]
5. Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".
Potenza MN; McDougle CJ
J Clin Psychopharmacol; 2001 Apr; 21(2):246-7. PubMed ID: 11270929
[No Abstract] [Full Text] [Related]
6. Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".
Demb HB; Roychoudhury K
J Clin Psychopharmacol; 2000 Oct; 20(5):580-1. PubMed ID: 11001245
[No Abstract] [Full Text] [Related]
7. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
[TBL] [Abstract][Full Text] [Related]
8. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Frazier JA; Biederman J; Tohen M; Feldman PD; Jacobs TG; Toma V; Rater MA; Tarazi RA; Kim GS; Garfield SB; Sohma M; Gonzalez-Heydrich J; Risser RC; Nowlin ZM
J Child Adolesc Psychopharmacol; 2001; 11(3):239-50. PubMed ID: 11642474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olanzapine in social anxiety disorder: a pilot study.
Barnett SD; Kramer ML; Casat CD; Connor KM; Davidson JR
J Psychopharmacol; 2002 Dec; 16(4):365-8. PubMed ID: 12503837
[TBL] [Abstract][Full Text] [Related]
10. Open-label olanzapine treatment in five preadolescent children.
Krishnamoorthy J; King BH
J Child Adolesc Psychopharmacol; 1998; 8(2):107-13. PubMed ID: 9730076
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.
McCracken JT; Suddath R; Chang S; Thakur S; Piacentini J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):501-8. PubMed ID: 18928414
[TBL] [Abstract][Full Text] [Related]
12. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
Stigler KA; Diener JT; Kohn AE; Li L; Erickson CA; Posey DJ; McDougle CJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):265-74. PubMed ID: 19519261
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label trial of olanzapine in adolescents with schizophrenia.
Findling RL; McNamara NK; Youngstrom EA; Branicky LA; Demeter CA; Schulz SC
J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):170-5. PubMed ID: 12544176
[TBL] [Abstract][Full Text] [Related]
15. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF
J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842
[TBL] [Abstract][Full Text] [Related]
16. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.
Brodkin ES; McDougle CJ; Naylor ST; Cohen DJ; Price LH
J Child Adolesc Psychopharmacol; 1997; 7(2):109-21. PubMed ID: 9334896
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH
Arch Gen Psychiatry; 1998 Jul; 55(7):633-41. PubMed ID: 9672054
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
